Astellas Pharma

4503.TApproved

Astellas Pharma Inc. is one of Japan's leading pharmaceutical companies with a global presence, dedicated to turning innovative science into value for patients. The company has built a strong portfolio of prescription medicines and is advancing multiple programs through clinical development, with particular expertise in urology, oncology, immunology, and neuroscience. Astellas is committed to becoming a global biopharmaceutical company by leveraging external innovation and strategic partnerships.

Market Cap

$26.8B

Employees

14,000-16,000

Focus

Biotech

4503.T · Stock Price

USD 2382.00+368.00 (+18.27%)

Historical price data

AI Company Overview

Technology Platform

Comprehensive drug discovery and development platform combining small molecule drugs, biologics, antibody-drug conjugates, and advanced drug delivery systems to address unmet medical needs across multiple therapeutic areas.

Pipeline Snapshot

1000

1000 drugs in pipeline, 248 in Phase 3

Drug	Indication	Stage
ASP1941 + metformin + Placebo	Type II Diabetes Mellitus	Phase 3
roxadustat + DA	Chronic Kidney Disease	Phase 3
Tacrolimus	Kidney Transplantation	Phase 3
tacrolimus	Liver Transplantation	Phase 3
Minodronic acid hydrate	Involutional Osteoporosis	Phase 3

Funding History

IPOUndisclosedUndisclosedApr 15, 2005

FDA Approved Drugs

VYLOYBLAOct 18, 2024

IZERVAYNDAAug 4, 2023

VEOZAHNDAMay 12, 2023

Opportunities

Astellas has significant growth opportunities through its expanding oncology pipeline, potential geographic expansion of key products, and strategic partnerships in emerging technologies like cell and gene therapy.

The company's focus on precision medicine and personalized therapies positions it well for the evolving healthcare landscape.

Risk Factors

Key risks include patent cliff exposure for major products like Xtandi, intense competition in core therapeutic areas, and execution risks associated with late-stage clinical programs.

Regulatory challenges and potential safety issues with investigational compounds also represent significant concerns.

Competitive Landscape

Astellas competes with major global pharmaceutical companies including Pfizer, Novartis, and Roche across its therapeutic areas. The company differentiates itself through specialized expertise in urology, growing oncology presence, and strategic focus on areas with high unmet medical needs, though faces increasing competition from both established players and emerging biotech companies.

Publications

Patents

Pipeline

1000

FDA Approvals